{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T22:34:05Z","timestamp":1790202845783,"version":"4.1.0"},"reference-count":45,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T00:00:00Z","timestamp":1772755200000},"content-version":"vor","delay-in-days":2,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,3,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background and objectives<\/jats:title>\n                    <jats:p>Fluoroquinolones are linked with increased risk of CNS adverse events, such as anxiety and depression. Recently, case reports have linked fluoroquinolone use and panic attacks. However, current evidence exploring the link between fluoroquinolone use and panic attacks remains limited and requires investigation for safe use. To systematically review the literature on fluoroquinolone use and the risk of panic attacks, and to study this association by comparing fluoroquinolones with other antibiotics using the FDA Adverse Event Reporting System (FAERS) database.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>MEDLINE and Embase databases were searched to identify relevant studies for systematic review. Active-comparator restricted disproportionality analyses using FAERS (2004Q1-2024Q4) were performed for ciprofloxacin, levofloxacin, and moxifloxacin compared to azithromycin and trimethoprim\/sulfamethoxazole. Reporting odds ratios (ROR), proportional reporting ratios, adjusted ROR for potential confounders, and Bayesian analyses were conducted to detect safety signals for MedDRA term \u2018panic attack\u2019.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The systematic review identified 12 studies (4 clinical trials, 8 publications describing 11 case reports), with the prevalence of panic attacks ranging between 0.46% and 1.76% in trials. Disproportionality analysis showed that, compared to azithromycin, fluoroquinolones were associated with a 6-fold increase in reports of panic attacks and a 12-fold increase compared to trimethoprim\/sulfamethoxazole. Results were consistent across Bayesian analyses.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The findings suggest an association between fluoroquinolones and increased risk of panic attacks, underscoring the need for validation through pharmacoepidemiological studies. Due to reliance on spontaneous reports, causal relationships cannot be determined for clinical recommendations. These results offer insights for research on CNS safety profiles of fluoroquinolones.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/jac\/dkag083","type":"journal-article","created":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T12:22:26Z","timestamp":1771849346000},"source":"Crossref","is-referenced-by-count":2,"title":["Fluoroquinolones and the risk of panic attacks: a systematic review and disproportionality analysis using individual case safety reports from the FDA Adverse Event Reporting System (FAERS) database"],"prefix":"10.1093","volume":"81","author":[{"given":"Keeirah Hiertika","family":"Raguram","sequence":"first","affiliation":[{"name":"Department of Physiology and Pharmacology, Western University , London, Ontario ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manroop","family":"Sidhu","sequence":"additional","affiliation":[{"name":"Department of Physiology and Pharmacology, Western University , London, Ontario ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6847-0699","authenticated-orcid":false,"given":"Mohammad Ali","family":"Omrani","sequence":"additional","affiliation":[{"name":"Department of Physiology and Pharmacology, Western University , London, Ontario ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bala Swetha","family":"Baskaran","sequence":"additional","affiliation":[{"name":"Department of Physiology and Pharmacology, Western University , London, Ontario ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niaz","family":"Chalabianloo","sequence":"additional","affiliation":[{"name":"Department of Physiology and Pharmacology, Western University , London, Ontario ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manik","family":"Chhabra","sequence":"additional","affiliation":[{"name":"ICES Western , Kidney, Dialysis & Transplantation Research Program, London, Ontario ,","place":["Canada"]},{"name":"Department of Epidemiology and Biostatistics, Western University , London, Ontario ,","place":["Canada"]},{"name":"London Health Sciences Centre, Lawson Health Research Institute , London, Ontario ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hugues","family":"Sampasa-Kanyinga","sequence":"additional","affiliation":[{"name":"Healthy Active Living and Obesity Research Group, Children's Hospital of Eastern Ontario Research Institute , Ottawa, Ontario ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4682-6564","authenticated-orcid":false,"given":"Flory Tsobo","family":"Muanda","sequence":"additional","affiliation":[{"name":"Department of Physiology and Pharmacology, Western University , London, Ontario ,","place":["Canada"]},{"name":"ICES Western , Kidney, Dialysis & Transplantation Research Program, London, Ontario ,","place":["Canada"]},{"name":"Department of Epidemiology and Biostatistics, Western University , London, Ontario ,","place":["Canada"]},{"name":"London Health Sciences Centre, Lawson Health Research Institute , London, Ontario ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,3,6]]},"reference":[{"key":"2026030611191018100_dkag083-B1","doi-asserted-by":"publisher","first-page":"120440","DOI":"10.1016\/J.ENVPOL.2022.120440","article-title":"Fluoroquinolone antibiotics: occurrence, mode of action, resistance, environmental detection, and remediation \u2013 A comprehensive review","volume":"315","author":"Bhatt","year":"2022","journal-title":"Environ Pollut"},{"key":"2026030611191018100_dkag083-B2","doi-asserted-by":"publisher","first-page":"108","DOI":"10.3390\/ANTIBIOTICS8030108","article-title":"Revisiting oral Fluoroquinolone and multivalent cation drug-drug interactions: are they still relevant?","volume":"8","author":"Pitman","year":"2019","journal-title":"Antibiotics"},{"key":"2026030611191018100_dkag083-B3","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.3390\/PH16081105\/S1","article-title":"Depressive and other adverse CNS effects of Fluoroquinolones","volume":"16","author":"Wierzbi\u0144ski","year":"2023","journal-title":"Pharmaceuticals"},{"key":"2026030611191018100_dkag083-B4","doi-asserted-by":"publisher","first-page":"161","DOI":"10.18773\/AUSTPRESCR.2021.035","article-title":"Fluoroquinolone antibiotics and adverse events","volume":"44","author":"Baggio","year":"2021","journal-title":"Aust Prescr"},{"key":"2026030611191018100_dkag083-B5","doi-asserted-by":"publisher","first-page":"1843","DOI":"10.3390\/ANTIBIOTICS11121843","article-title":"The blood\u2013brain barrier and pharmacokinetic\/pharmacodynamic optimization of antibiotics for the treatment of central nervous system infections in adults","volume":"11","author":"Haddad","year":"2022","journal-title":"Antibiotics"},{"key":"2026030611191018100_dkag083-B6","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/BMJ.N71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"2026030611191018100_dkag083-B7","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/J.JCLINEPI.2022.05.022","article-title":"Searching two or more databases decreased the risk of missing relevant studies: a metaresearch study","volume":"149","author":"Ewald","year":"2022","journal-title":"J Clin Epidemiol"},{"key":"2026030611191018100_dkag083-B8","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1176\/APPI.BOOKS.9780890425787.X05_ANXIETY_DISORDERS","volume-title":"Diagnostic and Statistical Manual of Mental Disorders","author":"American Psychiatric Association","year":"2022"},{"key":"2026030611191018100_dkag083-B9"},{"key":"2026030611191018100_dkag083-B10","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1002\/PHAR.1496","article-title":"Evaluation of the reproducibility of the Naranjo Adverse Drug Reaction Probability Scale score in published case reports","volume":"34","author":"Liang","year":"2014","journal-title":"Pharmacotherapy"},{"key":"2026030611191018100_dkag083-B11","doi-asserted-by":"publisher","first-page":"l4898","DOI":"10.1136\/BMJ.L4898","article-title":"Rob 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"2026030611191018100_dkag083-B12","doi-asserted-by":"publisher","first-page":"3055","DOI":"10.1038\/s41433-023-02454-7","article-title":"Interpreting results from randomized controlled trials: what measures to focus on in clinical practice","volume":"37","author":"Darzi","year":"2023","journal-title":"Eye"},{"key":"2026030611191018100_dkag083-B13","doi-asserted-by":"publisher","first-page":"2421","DOI":"10.1093\/JAC\/DKAF231","article-title":"Trimethoprim\/sulfamethoxazole and risk of haemophagocytic lymphohistiocytosis (HLH): a literature review and disproportionality analysis using individual case safety reports from FAERS","volume":"80","author":"Lau","year":"2025","journal-title":"J Antimicrob Chemother"},{"key":"2026030611191018100_dkag083-B14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/14740338.2025.2568242","article-title":"Auditory system adverse events with sacubitril\/valsartan: an active-comparator restricted disproportionality analysis using the FDA adverse event reporting system database","author":"Jafari","year":"2025","journal-title":"Expert Opin Drug Saf"},{"key":"2026030611191018100_dkag083-B15","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1111\/BCP.15178","article-title":"Active-comparator restricted disproportionality analysis for pharmacovigilance signal detection studies of chronic disease medications: an example using sodium\/glucose cotransporter 2 inhibitors","volume":"89","author":"Alkabbani","year":"2023","journal-title":"Br J Clin Pharmacol"},{"key":"2026030611191018100_dkag083-B16","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1007\/S40264-024-01423-7\/TABLES\/2","article-title":"The reporting of A disproportionality analysis for drug safety signal detection using individual case safety reports in PharmacoVigilance (READUS-PV): explanation and elaboration","volume":"47","author":"Fusaroli","year":"2024","journal-title":"Drug Saf"},{"key":"2026030611191018100_dkag083-B17","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1093\/JAMIA\/OCV153","article-title":"OpenFDA: an innovative platform providing access to a wealth of FDA\u2019s publicly available data","volume":"23","author":"Kass-Hout","year":"2016","journal-title":"J Am Med Inform Assoc"},{"key":"2026030611191018100_dkag083-B18","doi-asserted-by":"publisher","first-page":"574","DOI":"10.3233\/978-1-61499-564-7-574","article-title":"Observational Health Data Sciences and Informatics (OHDSI): opportunities for observational researchers","volume":"216","author":"Hripcsak","year":"2015","journal-title":"Stud Health Technol Inform"},{"key":"2026030611191018100_dkag083-B19","doi-asserted-by":"publisher","first-page":"e0331940","DOI":"10.1371\/JOURNAL.PONE.0331940","article-title":"Enhancing adverse drug reaction data quality in Canada: a high-precision pipeline for medication name standardization and enrichment","volume":"20","author":"Chalabianloo","year":"2025","journal-title":"PLoS One"},{"key":"2026030611191018100_dkag083-B20","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1002\/PDS.677","article-title":"Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports","volume":"10","author":"Evans","year":"2001","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"2026030611191018100_dkag083-B21","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1002\/PDS.1001","article-title":"The reporting odds ratio and its advantages over the proportional reporting ratio","volume":"13","author":"Rothman","year":"2004","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"2026030611191018100_dkag083-B22","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1590\/S1413-86702002000400001","article-title":"Treatment of adults with community-acquired respiratory tract infections: results of a multicentric clinical trial with gatifloxacin","volume":"6","author":"Medeiros","year":"2002","journal-title":"Braz J Infect Dis"},{"key":"2026030611191018100_dkag083-B23","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/S0924-8579(98)00039-9","article-title":"Efficacy and safety of high dose intravenous ciprofloxacin in the treatment of bacterial pneumonia","volume":"10","author":"Periti","year":"1998","journal-title":"Int J Antimicrob Agents"},{"key":"2026030611191018100_dkag083-B24","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/J.IJANTIMICAG.2006.11.033","article-title":"Levofloxacin 500mg once daily versus cefuroxime 250mg twice daily in patients with acute exacerbations of chronic obstructive bronchitis: clinical efficacy and exacerbation-free interval","volume":"30","author":"Petitpretz","year":"2007","journal-title":"Int J Antimicrob Agents"},{"issue":"Suppl 2","key":"2026030611191018100_dkag083-B25","doi-asserted-by":"publisher","first-page":"488","DOI":"10.2165\/00003495-199500492-00145\/METRICS","article-title":"Initial clinical experience with clinafloxacin in the treatment of serious infections","volume":"49","author":"Tack","year":"1995","journal-title":"Drugs"},{"key":"2026030611191018100_dkag083-B26","doi-asserted-by":"publisher","first-page":"1722","DOI":"10.1016\/j.jvir.2023.06.010","article-title":"Driving patients crazy: acute neuropsychiatric toxicities of commonly prescribed antibiotics in IR","volume":"34","author":"Abusafiyah","year":"2023","journal-title":"J Vasc Interv Radiol"},{"key":"2026030611191018100_dkag083-B27","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1258\/095646203322301121","article-title":"Psychiatric side effects of ofloxacin used in the treatment of pelvic inflammatory disease","volume":"14","author":"Hall","year":"2003","journal-title":"Int J STD AIDS"},{"key":"2026030611191018100_dkag083-B28","doi-asserted-by":"publisher","first-page":"212","DOI":"10.4103\/0976-3147.98256","article-title":"Levofloxacin-induced acute anxiety and insomnia","volume":"3","author":"Kandasamy","year":"2012","journal-title":"J Neurosci Rural Pract"},{"key":"2026030611191018100_dkag083-B29","doi-asserted-by":"publisher","first-page":"123","DOI":"10.4103\/IJP.IJP_291_17","article-title":"Levofloxacin-induced tactile hallucination and acute anxiety reaction","volume":"51","author":"Maharani","year":"2019","journal-title":"Indian J Pharmacol"},{"key":"2026030611191018100_dkag083-B30","doi-asserted-by":"publisher","first-page":"294","DOI":"10.4103\/2279-042X.192457","article-title":"Moxifloxacin-induced acute psychosis: a case report with literature review","volume":"5","author":"Mazhar","year":"2016","journal-title":"J Res Pharm Pract"},{"key":"2026030611191018100_dkag083-B31","doi-asserted-by":"publisher","first-page":"e6217","DOI":"10.7759\/CUREUS.6217","article-title":"Levofloxacin-induced psychosis in a young healthy patient","volume":"11","author":"Muradian","year":"2019","journal-title":"Cureus"},{"key":"2026030611191018100_dkag083-B32","first-page":"197","article-title":"Severe and symptomatic hyponatraemia after moxifloxacin intake","volume":"67","author":"M\u00fcssig","year":"2009","journal-title":"Neth J Med"},{"key":"2026030611191018100_dkag083-B33","doi-asserted-by":"publisher","first-page":"e87","DOI":"10.4081\/CP.2012.E87","article-title":"Fluoroquinolone toxicity symptoms in a patient presenting with low back pain","volume":"2","author":"Strauchman","year":"2012","journal-title":"Clin Pract"},{"key":"2026030611191018100_dkag083-B34","doi-asserted-by":"publisher","first-page":"54","DOI":"10.12788\/JCSO.0167","article-title":"Fluoroquinolone-related neuropsychiatric and mitochondrial toxicity: a collaborative investigation by scientists and members of a social network","volume":"14","author":"Kaur","year":"2016","journal-title":"J Community Support Oncol"},{"key":"2026030611191018100_dkag083-B35","doi-asserted-by":"publisher","first-page":"1435923","DOI":"10.3389\/fphar.2024.1435923","article-title":"Psychiatric disorders associated with fluoroquinolones: a pharmacovigilance analysis of the FDA adverse event reporting system database","volume":"15","author":"Xie","year":"2024","journal-title":"Front Pharmacol"},{"key":"2026030611191018100_dkag083-B36","doi-asserted-by":"publisher","first-page":"e54565","DOI":"10.7759\/cureus.54565","article-title":"Fluoroquinolones: neurological complications and Side effects in clinical practice","volume":"16","author":"Anwar","year":"2024","journal-title":"Cureus"},{"key":"2026030611191018100_dkag083-B37","doi-asserted-by":"publisher","first-page":"1491921","DOI":"10.3389\/fphar.2024.1491921","article-title":"Which fluoroquinolone is safer when combined with bedaquiline for tuberculosis treatment: evidence from FDA adverse event reporting system database from 2013 to 2024","volume":"15","author":"Wei","year":"2024","journal-title":"Front Pharmacol"},{"key":"2026030611191018100_dkag083-B38","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1177\/02698811251344684","article-title":"Fluoroquinolones and risk of nightmares: a literature review and disproportionality analysis using individual case safety reports from food and drug administration adverse event reporting system database","volume":"39","author":"Omrani","year":"2025","journal-title":"J Psychopharmacol"},{"key":"2026030611191018100_dkag083-B39","doi-asserted-by":"publisher","first-page":"33","DOI":"10.3390\/MEDICINES10060033","article-title":"Fluoroquinolone-associated movement disorder: a literature review","volume":"10","author":"Rissardo","year":"2023","journal-title":"Med"},{"key":"2026030611191018100_dkag083-B40","doi-asserted-by":"publisher","first-page":"2503","DOI":"10.1007\/s00213-016-4300-3","article-title":"Quinolone antibiotics and suicidal behavior: analysis of the World Health Organization\u2019s adverse drug reactions database and discussion of potential mechanisms","volume":"233","author":"Samyde","year":"2016","journal-title":"Psychopharmacology (Berl)"},{"key":"2026030611191018100_dkag083-B41","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1136\/BMJ.38701.399942.63","article-title":"Case reports of suspected adverse drug reactions\u2014systematic literature survey of follow-up","volume":"332","author":"Loke","year":"2006","journal-title":"BMJ"},{"key":"2026030611191018100_dkag083-B42","doi-asserted-by":"publisher","first-page":"108857","DOI":"10.1016\/J.EXER.2021.108857","article-title":"Effects of fluoroquinolones and tetracyclines on mitochondria of human retinal MIO-M1 cells","volume":"214","author":"Salimiaghdam","year":"2022","journal-title":"Exp Eye Res"},{"key":"2026030611191018100_dkag083-B43","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1002\/PDS.3529","article-title":"Assessing the extent and impact of the masking effect of disproportionality analyses on two spontaneous reporting systems databases","volume":"23","author":"Maignen","year":"2014","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"2026030611191018100_dkag083-B44","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1177\/0018578719882323","article-title":"Existence of notoriety bias in FDA adverse event reporting system database and its impact on signal strength","volume":"56","author":"Neha","year":"2021","journal-title":"Hosp Pharm"},{"key":"2026030611191018100_dkag083-B45","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/J.JCLINEPI.2021.06.022","article-title":"High prevalence of spin was found in pharmacovigilance studies using disproportionality analyses to detect safety signals: a meta-epidemiological study","volume":"138","author":"Mouffak","year":"2021","journal-title":"J Clin Epidemiol"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/81\/4\/dkag083\/67259687\/dkag083.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/81\/4\/dkag083\/67259687\/dkag083.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T16:19:17Z","timestamp":1772813957000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article\/doi\/10.1093\/jac\/dkag083\/8509341"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,4]]},"references-count":45,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,3,4]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dkag083","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"value":"0305-7453","type":"print"},{"value":"1460-2091","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,4]]},"published":{"date-parts":[[2026,3,4]]},"article-number":"dkag083"}}